Chunyu Jia

Chunyu Jia

Auto-generated profile, based on publicly available information

Chunyu Jia

Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SZShengnan Zhang
Shengnan Zhang
YLYu-Qing Liu
Yu-Qing Liu
CJChunyu Jia
Chunyu Jia
YLYeh-Jun Lim
Yeh-Jun Lim
GFGuoqin Feng
Guoqin Feng
CLCong Liu
Cong Liu
Significance: Receptor-mediated cell-to-cell transmission of pathological α-synuclein (α-syn) plays an important role in the progression of Parkinson’s disease (PD). We show that α-syn uses its acidic C terminus to bind an alkaline patch on the receptors. The formation of amyloid fibrils dramatically enhances the binding by condensing α-syn molecules and better exposing the C terminus. Moreover, S129 phosphorylation, a hallmark modification of α-syn accumulation in Lewy bodies, further strengthens the electrostatic interactions between α-syn and the receptors, which accelerates the PD-like pathology in mice. This work illuminates mechanistic understanding on the spread of pathological proteins and provides structural information for the therapeutic targeting of pathological α-syn spread in PD progression.

1 June 2021 in Vaccine
Verified
Journal Article
Open access
YWYanxia Wang
Yanxia Wang
YZYuhui Zhang
Yuhui Zhang
HWHaofei Wu
Haofei Wu
LHLili Huang
Lili Huang
HYHailong Yu
Hailong Yu
SWShuai Wang
Shuai Wang
Quadrivalent influenza inactivated vaccine (IIV4) is more likely to provide wider protection against yearly circulating influenza viruses than trivalent inactivated influenza vaccine (IIV3). In this study, a total of 320 participants were allocated to four age cohorts (6-35 months, 3-8 years, 9-17 years, and ≥ 18 years; 80 participants/cohort) according to their actual date of birth. Participants in each cohort were randomly assigned to two groups to receive intramuscular injection of the trial vaccine or the comparative vaccine in a one-dose (3-8 years, 9-17 years,and ≥ 18 years) schedule on day 0 or two-dose (6-35 months cohort) schedule on day 0 and 28. The first objective is to evaluate the safety and immunogenicity of the full-dose subunit non-adjuvanted IIV4 (FD-subunit NAIIV4) we developed versus an active-control, China-licensed split-virion NAIIV4, in people ≥ 3 years. The second objective is to evaluate the safety and immunogenicity of FD-subunit NAIIV4 versus the half-dose (HD-subunit NAIIV4) in toddlers aged 6-35 months. Results showed that all adverse reactions noted were rare, mild, and self-limited. In ≥ 3 years cohorts, systemic adverse reactions in FD-subunit NAIIV4 groups were less than the active control split-virion NAIIV4 groups ([Systemic adverse reaction rates (95%CI)], 15.0 (8.6-21.4) versus 19.2(12.1-26.2), p = 0.391). The overall seroprotection efficacy after vaccination were comparable between FD-subunit NAIIV4 and the active control split-virion NAIIV4([Seroprotection rates (95%CI)], H1N1, 99.2(81.3-100.0) versus 94.9(90.9-98.9), p = 0.117; H3N2, 81.7(74.7-88.6) versus 82.1(75.1-89.0), p = 0.939; BV, 75.8(68.2-83.5) versus 74.4(66.4-82.3), p = 0.793; BY, 94.2(90.0-98.4) versus 92.3(87.5-97.1), p = 0.568). Additionally, FD-subunit NAIIV4 has comparable safety and better seroprotection versus that of the half-dose in 6-35 months toddlers groups ([Total adverse reaction rates (95%CI)], 37.5(18.5-56.5) versus 47.5(26.1-68.9), p = 0.366) ([Seroprotection rates (95%CI)], H1N1, 85(56.4-100.0) versus 75.7(47.6-100.0), p = 0.117; H3N2, 50(28.1-71.9) versus 29.7(12.2-47.3), p = 0.070; BV, 75(48.2-100.0) versus 29.7(12.2-47.3), p < 0.001; BY, 75(48.2-100.0) versus 56.8(32.5-81.0), p = 0.091). As a result, the FD-subunit NAIIV4 we developed is safe and effective to provide broader and adequate protection against the circulating influenza viruses during 2018-2019, which could be an essential component of the global preventive strategy for influenza pandemic.